Table 6:
Interventions and Comparators Evaluated in the Primary Economic Model
| Intervention | Comparator | Comparator Dosing | Source |
|---|---|---|---|
| LAAC device | Apixaban | 5 mg twice daily or 2.5 mg if patient has one or more of the following criteria: age ≥ 80 years, body weight < 60 kg, serum creatinine level ≥ 1.5 mg/dL | Granger et al, 201116 |
| LAAC device | Dabigatran | 150 mg twice daily or 110 mg twice daily if patient age ≥ 80 years and/or ≥ 75 years with a creatinine clearance of 30–50 mL/min | Boehringer Ingelheim Canada45 |
| LAAC device | Rivaroxaban | 20 mg daily or 15 mg daily if patient has a creatinine clearance of 30–49 mL/min | Patel et al, 201117 |
| LAAC device | Warfarin | Adjusted-dose, target INR 2–3 | Bristol-Myers Squibb Canada46; Connolly et al, 201315; Granger et al, 201116; Holmes et al, 201420; Patel et al, 201117; Reddy et al, 201340 |
Abbreviations: INR, international normalized ratio; LAAC device, left atrial appendage closure device with delivery system.